IL307646A - Dosing regimen for combination therapy targeting DLL3 and PD-1 - Google Patents

Dosing regimen for combination therapy targeting DLL3 and PD-1

Info

Publication number
IL307646A
IL307646A IL307646A IL30764623A IL307646A IL 307646 A IL307646 A IL 307646A IL 307646 A IL307646 A IL 307646A IL 30764623 A IL30764623 A IL 30764623A IL 307646 A IL307646 A IL 307646A
Authority
IL
Israel
Prior art keywords
combination therapy
dosing regimen
therapy targeting
targeting dll3
dll3
Prior art date
Application number
IL307646A
Other languages
English (en)
Hebrew (he)
Inventor
Nooshin Hashemi Sadraei
Aditya Shetty
Mukul Minocha
Marie-Ann Damiette Smit
Hansen Wong
Siddhartha Roychoudhury
Original Assignee
Amgen Inc
Nooshin Hashemi Sadraei
Aditya Shetty
Mukul Minocha
Smit Marie Ann Damiette
Hansen Wong
Siddhartha Roychoudhury
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Nooshin Hashemi Sadraei, Aditya Shetty, Mukul Minocha, Smit Marie Ann Damiette, Hansen Wong, Siddhartha Roychoudhury filed Critical Amgen Inc
Publication of IL307646A publication Critical patent/IL307646A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL307646A 2021-05-10 2022-05-06 Dosing regimen for combination therapy targeting DLL3 and PD-1 IL307646A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163186569P 2021-05-10 2021-05-10
PCT/US2022/028135 WO2022240688A1 (en) 2021-05-10 2022-05-06 Dosing regimen for combination therapy targeting dll3 and pd-1

Publications (1)

Publication Number Publication Date
IL307646A true IL307646A (en) 2023-12-01

Family

ID=84029376

Family Applications (1)

Application Number Title Priority Date Filing Date
IL307646A IL307646A (en) 2021-05-10 2022-05-06 Dosing regimen for combination therapy targeting DLL3 and PD-1

Country Status (12)

Country Link
US (1) US20240317856A1 (enExample)
EP (1) EP4337252A4 (enExample)
JP (1) JP2024518947A (enExample)
KR (1) KR20240006585A (enExample)
CN (1) CN117377488A (enExample)
AU (1) AU2022273509A1 (enExample)
CA (1) CA3217141A1 (enExample)
CL (1) CL2023003357A1 (enExample)
IL (1) IL307646A (enExample)
MX (1) MX2023013227A (enExample)
TW (1) TW202309092A (enExample)
WO (1) WO2022240688A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス，インコーポレーテッド ＮＫｐ３０に結合する抗体分子およびその使用
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
EP4482586A1 (en) * 2022-02-23 2025-01-01 Amgen Inc. Cancer treatment targeting dll3
KR20250116698A (ko) * 2022-12-08 2025-08-01 암젠 인크 Dll3-발현 암의 치료 방법
CN121620371A (zh) * 2023-05-19 2026-03-06 勃林格殷格翰国际公司 T细胞衔接蛋白在治疗癌症中的用途
CN120168667B (zh) * 2025-03-18 2026-04-14 中国科学院近代物理研究所 一种多肽在制备dll3过度表达的肿瘤的特异性靶向分子探针中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI793062B (zh) * 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
EP3337517A4 (en) * 2015-08-20 2019-04-17 Abbvie Stemcentrx LLC ANTI-DLL3 ANTIBODY AGGREGATE CONJUGATES AND METHOD OF USE
CR20200539A (es) * 2018-04-10 2021-07-01 Kite Pharma Inc Receptores quiméricos de dll3 y métodos para su uso
TWI848953B (zh) * 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白

Also Published As

Publication number Publication date
CN117377488A (zh) 2024-01-09
US20240317856A1 (en) 2024-09-26
MX2023013227A (es) 2024-01-29
EP4337252A1 (en) 2024-03-20
CA3217141A1 (en) 2022-11-17
AU2022273509A1 (en) 2023-10-19
KR20240006585A (ko) 2024-01-15
WO2022240688A1 (en) 2022-11-17
TW202309092A (zh) 2023-03-01
EP4337252A4 (en) 2025-04-23
JP2024518947A (ja) 2024-05-08
CL2023003357A1 (es) 2024-06-07

Similar Documents

Publication Publication Date Title
EP4337252A4 (en) DOSAGE REGIMEN FOR COMBINATION THERAPY TARGETING DLL3 AND PD-1
JOP20200116A1 (ar) طرق لعلاج أو الوقاية من الصداع النصفي
NZ720743A (en) Peptidomimetic compounds and antibody-drug conjugates thereof
IL292673A (en) Combined treatment by anti-pvrig antibody and anti-pd-1 antibody formulations
HK1222340A1 (zh) 抗folr1免疫缀合物给药方案
EP3989784A4 (en) Ground coffee dosing and packing
MX2013010446A (es) Regimenes de dosificacion para el tratamiento de la enfermedad de fabry.
EP3421039A4 (en) Drug for cancer therapy characterized by administering combination between axl inhibitor and immune checkpoint inhibitor
AU2018302999A1 (en) Treatment cancers using a combination comprising PARP inhibitors, temozolomide and/or radiation therapy
MX2016007826A (es) Compuestos peptidomimeticos y sus conjugados de anticuerpo-farmaco.
NZ705910A (en) Pyrrolobenzodiazepines and conjugates thereof
IL271849A (en) Targeting chromosomal instability and downstream cytosolic DNA signaling for cancer therapy
MX2020012755A (es) Regimenes de dosificacion del inmunoconjugado anti antigeno leucocitario (cd37).
NZ718766A (en) Anti-folr1 immunoconjugate dosing regimens
IL272669A (en) Combination therapy with a combination of anti-CSF1R and anti-PD-1 antibodies for pancreatic cancer
IL314195A (en) Cancer treatment targeting DLL3
EP3755371A4 (en) ANTI-CANCER TREATMENT COMBINED WITH ANTI-CANCER AGENTS AND ANTIBODIES TARGETING A COMPLEX INCLUDING A NON-CLASSIC HLA-I AND A NEO-ANTIGEN
IL227611A0 (en) Treatment dosage, medication distribution package, and their uses for the treatment of depressive disorders
HK1253098A1 (zh) 用於治疗癌症的mdm2抑制剂的给药方案
NZ733669A (en) Antibody-urease conjugates for therapeutic purposes
IL254228A0 (en) Cell therapy agent for cancer treatment and combined therapy with it
WO2015175533A3 (en) Anti-cd37 immunoconjugate dosing regimens
IL270774A (en) Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells
IL288716B2 (en) Combination therapy that combines an anti-CD19 antibody drug with a PI3K inhibitor or a secondary factor
MX2019009630A (es) Programa de dosificacion de un inhibidor de wnt y una molecula de anticuerpo anti-pd-1 en combinacion.